Profile: NovaBay Pharmaceuticals Inc (NBY.A)
26 Jul 2016
NovaBay Pharmaceuticals, Inc., formerly NovaCal Pharmaceuticals, Inc., incorporated on April 19, 2010, is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox. Its Avenova with Neutrox removes debris from the skin on the eyelids and lashes without burning or stinging.
The Company develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. The Company has partnerships for NeutroPhase in the United States, as well as in other markets. The Company's products include Aganocide Compounds. The Aganocide compounds, led by auriclosene (NVC-422), are synthetic molecules with activity against bacteria, viruses and fungi. The Company's dermatology product includes CelleRx, a cleansing solution for post laser resurfacing, chemical peels and other cosmetic surgery procedures. The Company offers intelli-Case product, which is a device for the use with hydrogen peroxide disinfection solutions for gas permeable contact lenses. The Company has completed Phase II clinical study of auriclosene to manage urinary catheter encrustation and blockage (UCBE). The Company's wound care business includes the business of NeutroPhase product. Its NeutroPhase product is used to cleanse and remove microorganisms from acute or chronic wound, and can be used with different types of wound care modality.
NovaBay Pharmaceuticals Inc
5980 Horton St Ste 550
EMERYVILLE CA 94608-2045
Company Web Links
- BRIEF-Novabay Pharmaceuticals appoints Mark Sieczkarek president and CEO
- BRIEF-Novabay Pharmaceuticals files for offering of 581,423 shares of common stock issuable upon exercise of outstanding warrants
- BRIEF-Novabay Pharmaceuticals reports Q1 loss per share $1.24
- BRIEF-Novabay Pharmaceuticals appoints Todd Zavodnick to its board